Minerva Neurosciences | NERV - PE Price to Earnings


Minerva Neurosciences reported 14.32 in PE Price to Earnings for its fiscal quarter ending in March of 2021.





Pe Change Date
Acadia Pharmaceuticals 11.33 1.25 Jun/2026
Adma Biologics 15.02 14.71 Mar/2026
ALKERMES 135.81 96.48 Jun/2026
AstraZeneca 25.34 4.25 Jun/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
Bristol-Myers Squibb 16.14 7.06 Jun/2026
Cipla 35.82 12.26 Jun/2026
Clal Biotechnology 11.67 2.62 Dec/2022
Compugen 5.45 1.39 Mar/2026
CSL 16.16 9.59 Dec/2025
Eli Lilly 32.9 7.37 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 12.51 1.15 Jun/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
J&J 29.43 4.9 Jun/2026
Merck 32.26 15.74 Jun/2026
Neurocrine Biosciences 22.1 5.99 Jun/2026
Novartis 22.41 2.24 Jun/2026
Novavax 2.01 1.07 Dec/2025
Pfizer 11.48 2.16 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 18.96 7.12 Jun/2026
Takeda 24.4 22.12 Jun/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023